Physician profile
Christopher Chum
NPI 1144669532
$5,832.20
in general payments reported to CMS, 2019-2025
27 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $270 · 2021: $152 · 2022: $113 · 2023: $798 · 2024: $2,854 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,688 · Food and Beverage: $2,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,688.09 |
| Food and Beverage | $2,386.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,623.25 | 2023-2024 | Single Use Electrosurgical Knife Kd-655, Disposable Distal Attachment, Single Use Aspiration Needle Na-U200h |
| Boston Scientific Corporation | $956.10 | 2019-2024 | Orise, Spyscope Ds, Spyglass |
| Abbvie INC. | $595.96 | 2020-2025 | |
| Ovesco Endoscopy USA, INC. | $561.31 | 2024 | |
| Gilead Sciences, INC. | $385.79 | 2019-2024 | |
| Janssen Biotech, INC. | $172.71 | 2025 | Tremfya, Simponi Aria, Simponi |
| Cook Medical LLC | $166.37 | 2021-2024 | Hemospray, Fusion |
| Lilly USA, LLC | $161.92 | 2024-2025 | Omvoh |
| Olympus America INC. | $160.62 | 2019-2025 | Endoclot Phs |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.16 | 2024-2025 | Xifaxan |
| Pfizer INC. | $127.57 | 2025 | |
| Ardelyx, INC. | $98.50 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $96.14 | 2024-2025 | Zenpep, Vowst |
| Madrigal Pharmaceuticals | $92.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $77.69 | 2024-2025 | Entyvio, Eohilia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $66.73 | 2025 | Uplizna |
| Genzyme Corporation | $63.83 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $58.20 | 2024 | |
| Phathom Pharmaceuticals, INC. | $55.13 | 2025 | Voquezna |
| Steris Corporation | $44.92 | 2019-2021 | |
| Shionogi INC | $18.47 | 2019 | |
| Pharmacosmos Therapeutics INC. | $18.01 | 2025 | Monoferric |
| Novo Nordisk INC | $18.01 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $16.15 | 2024 | Dificid |
| Celgene Corporation | $16.13 | 2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $15.54 | 2025 | Iqirvo |
| Organon LLC | $14.90 | 2025 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.